AUM Biosciences Enters In A Strategic Collaboration With Handok And CMG Pharm To Develop CHC2014 New Pan-TRK Inhibitor For Cancer Treatment

AUM Biosciences (“AUM”), a global, clinical stage biotechnology company focused on discovering, acquiring and developing next generation targeted oncology therapeutics today announced it has entered into a strategic collaboration agreement with Handok Inc [002390: KOSPI] (“Handok”) and CMG Pharmaceutical Co. Ltd [KOSDAQ: 058820] (“CMG”) for the worldwide (ex-Korea) development, manufacturing and commercialisation rights of a highly specific, safe and efficacious Pan-TRK inhibitor. Financial terms of the agreement were not disclosed. CHC2014 is completing a Phase I in Korea and has shown promising data to justify advancement to a tumor agnostic registrational program. CHC2014 has shown superior in-vivo anti-tumor activity compared to available treatment options. It has shown strong efficacy on solvent front and gatekeeper mutations addressing a unique solution to the current challenge in TRK Inhibitor market. “We are glad to enter in a partnership with AUM to advance the global development of innovative targeted cancer therapy CHC2014, which is being co-developed by Handok-CMG-NOV and was successfully studied in phase 1 trial in Korea. After successful development of CHC2014 by AUM management with global capability, we expect that CHC2014 can help improving the lives of patients with rare cancers” commented by Young-Jin Kim, Chairman and CEO of Handok, Inc. “CHC2014, once developed as a new pan-TRK inhibitor, will provide another solution to cancer patients with TRK-fusion”, and “We expect AUM Biosciences specializing for target-specific anti-cancer small molecules to successful global development and commercialization of CHC2014 for the patients”, said Mr. Joohyung Lee, CEO of CMG Pharmaceutical. AUM “portfolio-model” strategy has made significant progress since its establishment through strategic collaborations and partnerships with leading academic institutions and pharmaceutical and biotech companies globally. “We thank Handok and CMG for its trust in AUM and its continued support in further developing the CHC2014 asset worldwide. We are very encouraged by the clear scientific and clinical differentiation that CHC2014 presents as compared to the other TRK inhibitors” commented Vishal Doshi, CEO, AUM Biosciences. “We are delighted to onboard Handok and CMG as a strategic investor in AUM” About AUM Biosciences AUM Biosciences is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. The management team has an extensive track record of selecting distinctive early stage assets, successfully exiting virtual biotech models, and have contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability and scalability.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!